Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

RELUGOLIX & ESTRADIOL & NORETHINDRONE ACETATE

All products: general benefit

Myfembree · DIN 02541742 · 40mg & 1mg & 0.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Myfembree · DIN 02541742 Manufacturer: Knight Therapeutics Inc.; listing date 2026-01-30 Health Canada: Marketed since 2025-10-28 · brand MYFEMBREE · ATC H01CC54 RELUGOLIX, ESTRADIOL AND NORETHISTERONE · form Tablet · route Oral · ingredients RELUGOLIX 40 MG, ESTRADIOL 1 MG, NORETHINDRONE ACETATE 0.5 MG · company Knight therapeutics inc. · schedule Prescription
Check this DIN again · Health Canada product record

Myfembree: Formulary list price $9.3150/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.3150 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103029 · Verify on the e-Formulary ↗ (DIN 02541742)

Source record
DIN 02541742: Myfembree Raw flags: sec3=Y Item: 681800021; group id 738; item number 1806; lccId None; manufacturer id KNT Source form: Tab; strength: 40mg & 1mg & 0.5mg Recorded listing: General benefit Source prices (unrounded): $9.3150; ministry $9.3150 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02541742 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103029
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02541742
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (68:00 HORMONES AND SUBSTITUTES) and how they are covered

Matched class: 68:00 HORMONES AND SUBSTITUTES

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, CANAGLIFLOZIN, CICLESONIDE, DANAZOL, DAPAGLIFLOZIN, DAPAGLIFLOZIN & METFORMIN, DESOGESTREL & ETHINYL ESTRADIOL, DROSPIRENONE, DROSPIRENONE & ETHINYL ESTRADIOL, EMPAGLIFLOZIN, EMPAGLIFLOZIN & METFORMIN, ESTRADIOL 17-B, ESTRADIOL HEMIHYDRATE, ESTRADIOL HEMIHYDRATE & PROGESTERONE, ETHINYL ESTRADIOL & NORETHINDRONE, ETHINYL ESTRADIOL & NORETHINDRONE ACETATE, ETONOGESTREL, FLUDROCORTISONE ACETATE, FLUTICASONE FUROATE, FLUTICASONE PROPIONATE, INSULIN (30% NEUTRAL & 70% ISOPHANE) HUMAN BIOSYNTHETIC, INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC, INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC (RDNA ORIGIN), INSULIN (ZINC CRYSTALLINE) HUMAN BIOSYNTHETIC (RDNA ORIGIN), INSULIN ASPART 30% & INSULIN ASPART PROTAMINE 70%, INSULIN DEGLUDEC, INSULIN DETEMIR, INSULIN GLARGINE & LIXISENATIDE, INSULIN GLULISINE (DNA ORIGIN), INSULIN HUMAN BIOSYNTHETIC, INSULIN HUMAN BIOSYNTHETIC 30% & ISOPHANE 70%, INSULIN INJECTION, HUMAN BIOSYNTHETIC, INSULIN LISPRO & INSULIN LISPRO PROTAMINE, LEVONORGESTREL, LINAGLIPTIN, LINAGLIPTIN & METFORMIN, METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, MOMETASONE FUROATE, PROPYLTHIOURACIL, RELUGOLIX, SAXAGLIPTIN, SAXAGLIPTIN & METFORMIN, SITAGLIPTIN, SITAGLIPTIN & METFORMIN, THYROTROPIN ALFA, TRIAMCINOLONE ACETONIDE Some products covered without a code (check the product listing): BUDESONIDE, CALCITONIN (SALMON SYNTHETIC), CONJUGATED ESTROGENS, DESMOPRESSIN ACETATE, DEXAMETHASONE, DEXAMETHASONE 21-PHOSPHATE, ESTRADIOL, ETHINYL ESTRADIOL & LEVONORGESTREL, GLICLAZIDE, GLYBURIDE, HYDROCORTISONE, INSULIN ASPART, INSULIN GLARGINE, INSULIN LISPRO, LEVOTHYROXINE (SODIUM), MEDROXYPROGESTERONE ACETATE, METFORMIN HCL, METHIMAZOLE, NORETHINDRONE, NORGESTIMATE & ETHINYL ESTRADIOL, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE 68:00 HORMONES AND SUBSTITUTES

RELUGOLIX

· 1 products · General benefit · strengths: 120mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:00 68:04 Corticosteroids

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 50mcg/Metered Dose, 100mcg/Metered Dose · Aero Inh-200 Dose Pk

BUDESONIDE

· 12 products · Limited Use, codes 260, 261, 262, 263, 264 (9), General benefit (3) · strengths: 0.125mg/mL, 0.25mg/mL, 0.5mg/mL, 100mcg/Metered Dose, 200mcg/Metered Dose, 400mcg/Metered Dose · Inh Susp, Pd Inh-200 Dose Pk

CICLESONIDE

· 3 products · General benefit · strengths: 100mcg/Actuation, 200mcg/Actuation, 50mcg/Actuation · Inh-120 Dose Pk, Metered Dose Nas Sp-120 Dose Pk

DEXAMETHASONE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 0.5mg, 4mg · Tab

DEXAMETHASONE 21-PHOSPHATE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 4mg/mL · Inj Sol

FLUDROCORTISONE ACETATE

· 2 products · General benefit · strengths: 0.1mg · Tab

FLUTICASONE FUROATE

· 2 products · General benefit · strengths: 100mcg, 200mcg · Blister Pd Inh-30 Dose Pk

FLUTICASONE PROPIONATE

· 14 products · General benefit · strengths: 50mcg/Metered Dose, 125mcg/Metered Dose, 250mcg/Metered Dose, 55mcg/Actuation, 113mcg/Actuation, 232mcg/Actuation, 250mcg/Blister, 500mcg/Blister · Inh-120 Dose Pk, Pd Inh-60 Dose Pk

HYDROCORTISONE

· 5 products · General benefit (4), Temporary benefit (1) · strengths: 10mg, 20mg · Tab

METHYLPREDNISOLONE

· 1 products · General benefit · strengths: 4mg · Tab

METHYLPREDNISOLONE ACETATE

· 3 products · General benefit · strengths: 40mg/mL, 80mg/mL, 100mg/5mL · Inj Susp-1mL Pk, Inj Susp-5mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:04 and 78 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS MYFEMBREE (relugolix, estradiol, and norethindrone acetate tablets) is indicated in premenopausal women for the management of heavy menstrual bleeding associated with uterine fibroids and for the management of moderate to severe pain associated with endometriosis. 1.1 Pediatrics Pediatrics (<18 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics: MYFEMBREE is not indicated in postmenopausal women and has not been studied in women over 50 years of age. https://pdf.hres.ca/dpd_pm/00082196.PDF PM date: OCT 13, 2023 Source product: MYFEMBREE; DIN 02541742; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.